gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Phase II trial of Docetaxel and Carboplatinum in recurrent platinum sensitive ovarian, peritoneal and tubal cancer - final results

Meeting Abstract

  • corresponding author presenting/speaker Hans-Georg Strauß - Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg , Deutschland
  • Alexander Henze - Klinik für Geburtshilfe und Gynäkologie, Aschaffenburg
  • Alexander Teichmann - Klinik für Geburtshilfe und Gynäkologie, Aschaffenburg
  • Ina Karbe - Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg
  • Anke Baumgart - Sanofi-Aventis Pharma GmbH
  • Christoph Thomssen - Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg
  • Heinz Kölbl - Klinik für Geburtshilfe und Gynäkologie, Johannes-Gutenberg-Universität Mainz

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocOP339

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 20. März 2006

© 2006 Strauß et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Recurrent ovarian, peritoneal or tubal cancer is associated with poor prognosis and short survival after salvage chemotherapy. We evaluated the efficacy and toxicity of combined chemotherapy with Docetaxel 75 mg/m2 – day 1 and Carboplatinum AUC 5 – day 1, every three weeks with a maximum of 6 cycles in platinum sensitive recurrent ovarian, peritoneal and tubal cancer. All patients included in our study had a recurrence free interval > 6 months after first line therapy. Either a histological confirmation of recurrence without measurable tumor by imaging associated with an elevated serum CA 125 > 35 U/ml or a bidimensionally measurable tumor was mandatory. An elevated serum CA 125 alone was not a sufficient entry criterion. Toxicities were graded according to the common toxicity criteria. 25 patients (22 ovarian, 2 peritoneal and 1 tubal cancer) were treated between 1999 and 2004 (median age 59.8 yrs., range 31 – 73 / performance status 0-2). 23/25 patients had at least two courses of chemotherapy and were evaluable for response and all patients were evaluable for toxicity. One patient refused further therapy after a single course without any reason; another patient due to a hypersensitivity reaction to Docetaxel in the first course. 22 / 25 patients (88.0%) had CA 125-sensitive recurrent tumor. The overall response rate was 78.3% (CR 69.6%, PR 8.7%). After a median follow-up of 29.4 months (range 7- 62) 14/16 patients with complete remission are alive, 10 still have no evidence of disease. The therapy was generally tolerated well and alopecia was ubiquitary. Grade 3-4 neutropenia was the predominant hematological toxicity (15 / 25 pts., 60%), but it was only in 1 patient associated with a febrile complication. GCSF was given in 15 / 103 courses (8 pts.). Grad 3 thrombocytopenia occurred in 5 / 25 pts. (20 %); Grade 4 thrombocytopenia in 1 patient. G3 diarrhea (3 pts.) and G3 depressive mood alterations (1 pt.) were the only G3 non-hematological toxicities. Combined treatment of Docetaxel and Carboplatinum represents a promising option for patients with platinum sensitive recurrent ovarian cancer, with an acceptable and manageable toxicity.